Phase II Study of Allovectin-7 as an Immunotherapeutic Agent in Patients With Stages III and IV Melanoma

Study Summary

RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.

Interventions

Study Locations

Facility	City	State	Country
Mayo Clinic Cancer Center	Rochester	Minnesota	United States
Roswell Park Cancer Institute	Buffalo	New York	United States
Physician Reliance Network, Inc.	Dallas	Texas	United States

Official Trial Information

View on ClinicalTrials.gov